slides · global inventory
50 Pareto Focus
Loop collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 778
Current window 451-480
Pages 26
Rows per page 30
Loop
451-480 of 778
15
The chart uses a waterfall-bridge structure to explain margin variance.Essity | Results Presentation Deck | 30 slides · Essity
Conference presentation Investor relations Beat · DevelopmentLoop · Pareto Focus1 hit
16
The slide serves as a visual transition to the Health & Medical segment of the presentation.Essity | Results Presentation Deck | 30 slides · Essity
Conference presentation Investor relations Beat · DevelopmentLoop · Pareto Focus1 hit
57
The slide uses a three-column layout: Actions, Enablers, and Financial Ambitions.Hugo Boss | Investor Day Presentation Deck | 107 slides · Hugo Boss
Conference presentation Investor relations Beat · VisualizationLoop · Pareto Focus1 hit
58
The slide uses a split-layout design with a photo on the left and quantitative metrics on the right.Hugo Boss | Investor Day Presentation Deck | 107 slides · Hugo Boss
Conference presentation Investor relations Beat · VisualizationLoop · Pareto Focus1 hit
59
Hugo Boss | Investor Day Presentation Deck | 107 slidesHugo Boss | Investor Day Presentation Deck | 107 slides · Hugo Boss
Conference presentation Investor relations Beat · VisualizationLoop · Pareto Focus1 hit
60
Hugo Boss | Investor Day Presentation Deck | 107 slidesHugo Boss | Investor Day Presentation Deck | 107 slides · Hugo Boss
Conference presentation Investor relations Beat · VisualizationLoop · Pareto Focus1 hit
22
The chart demonstrates deepening clinical responses over time for NXC-201 therapy.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
23
The table uses a red dashed box to highlight the core clinical data rows.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
24
The slide highlights specific safety data points for a competitor product to establish a benchmark.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
25
The slide uses a structured table format to map clinical trial progress against specific disease indications.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
26
The diagram illustrates a dose escalation study design with three cohorts leading to the RP2D.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
27
The slide features a scientific illustration of cellular structures, likely representing the drug delivery mechanism.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
28
Includes scientific diagrams of molecular pathways and comparative efficacy charts.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
29
The slide uses three bar charts to compare IMX-110 performance against benchmarks in mouse models.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
30
Includes a process diagram illustrating the mechanism of action of IMX-110 in tumor microenvironments.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
31
Includes survival curves (Kaplan-Meier), tumor imaging, and tumor frequency metrics.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
32
Immix Biopharma | Investor Presentation Deck | 49 slidesImmix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
33
Includes two side-by-side clinical data visualizations (line charts and bar charts) comparing patient outcomes.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
34
The slide uses a bubble chart to map clinical trial outcomes against patient treatment history and a table to detail specific drug performance metrics.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
35
The chart is a conceptual visualization of 100% of patients achieving 4 months mPFS.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
36
Shows two parallel clinical tracks: monotherapy and combination with tislelizumab.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
36
The chart compares the combined market size of major CPIs ($42B) against Libtayo ($0.5B) to illustrate the growth potential.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Pareto Focus1 hit
37
The slide uses a table-like layout to associate logos with market cap figures, followed by specific acquisition deal context.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Pareto Focus1 hit
14
The slide is purely visual/thematic, serving as a section divider.Sonder | Investor Presentation Deck | 27 slides · Sonder
Pitch deck Investor relations Beat · FinancialsLoop · Pareto Focus1 hit
15
The slide uses a dual-axis bar chart to show the trend of revenue (positive) and free cash flow (negative but improving).Sonder | Investor Presentation Deck | 27 slides · Sonder
Pitch deck Investor relations Beat · FinancialsLoop · Pareto Focus1 hit
16
The slide highlights Sonder's consistent outperformance of industry peers in RevPAR.Sonder | Investor Presentation Deck | 27 slides · Sonder
Pitch deck Investor relations Beat · FinancialsLoop · Pareto Focus1 hit
17
The slide highlights both historical performance and future pipeline visibility.Sonder | Investor Presentation Deck | 27 slides · Sonder
Pitch deck Investor relations Beat · FinancialsLoop · Pareto Focus1 hit
18
The chart uses a baseline to show negative growth for several major hotel chains.Sonder | Investor Presentation Deck | 27 slides · Sonder
Pitch deck Investor relations Beat · FinancialsLoop · Pareto Focus1 hit
19
The slide uses a bridge-style visual to connect historical performance to future goals via specific operational initiatives.Sonder | Investor Presentation Deck | 27 slides · Sonder
Pitch deck Investor relations Beat · FinancialsLoop · Pareto Focus1 hit
20
The slide uses a stacked bar chart to demonstrate operational efficiency improvements.Sonder | Investor Presentation Deck | 27 slides · Sonder
Pitch deck Investor relations Beat · FinancialsLoop · Pareto Focus1 hit